This presentation will cover the current status of CBD product regulation and where future regulation is likely headed. FDA’s position on marketed CBD products and claims will be covered as will permitted types of CBD products. The FDA May 2019 meeting on CBD will be reviewed and recent FDA enforcement actions regarding CBD claims will be discussed and advice is given on how to avoid FDA Warning Letters and problems with FDA regarding CBD product marketing. The new USDA regulation on Hemp production will also be discussed.

Learning Objectives:-

• Current status of CBD regulation and likely plans for future regulation
• FDA position on marketed CBD products and claims
• Permitted types of CBD products
• Highlights of FDA May 30, 2019 Meeting on CBD
• FDA Enforcement Actions RE: CBD Claims
• What’s Next for CBD product Marketing

Why Should You Attend?

This session will convey an understanding of likely FDA plans to address the challenging regulation of Cannabidiol (CBD) in different categories (drugs, food, dietary supplements, etc) and what actions the FDA has been taking regarding CBD claims that violate the law. The benefits will be learning how to market CBD products without getting into trouble with the FDA and what to expect for future regulation re CBD products.

Attendees will achieve a better understanding of how the FDA currently views CBD products and how to market products without violating FDA or Federal Trade Commission (FTC) regulations and getting into trouble. They will also have a better understanding of where FDA regulations are headed in the future. They will also obtain information about the recently passed USDA regulation on Hemp production and its’ new requirements.

Who Should Attend?

• Regulatory Affairs professionals
• Companies marketing CBD products
• Quality Assurance managers
• Organizations interested in CBD products
• Manufacturers and Distributors of CBD products